Sandoz plans $300 million biosimilar facility in Ljubljana
Sandoz Group plans to invest around $300 million to build a new biosimilar manufacturing facility in Ljubljana, Slovenia. The facility is expected to start operations in 2029 and add 8,000 litres of production capacity.
Sandoz Group AG said on Tuesday it plans to invest around $300 million to build a new biosimilar manufacturing facility in Ljubljana, Slovenia. The facility is expected to start operations in 2029 and will add 8,000 litres of production capacity.